Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor
December 13 2018 - 8:30AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new
technologies to create step-change improvements in crop yield that
enhance global food security, today named Sherri M. Brown, Ph.D.,
as a special commercial and technical advisor to the Company,
effective immediately. Dr. Brown is currently managing director of
The Yield Lab, a global agrifood tech accelerator based in St.
Louis. She previously served in a number of leadership positions
involving the development and global commercialization of new
biotechnology traits for canola, soybean and corn at Monsanto
Company for 28 years.
“We are delighted to welcome Dr. Brown, an agricultural industry
leader of tremendous caliber, to a crucial advisory role with
Yield10. She possesses a wealth of experience leading teams that
have successfully developed and commercialized innovative
biotechnology traits globally in canola, soybean and corn,” said
Oliver Peoples, Ph.D., president and chief executive officer of
Yield10. “Her extensive background in plant science, the assessment
of yield traits in the field, global experience, and knowledge of
the commercial landscape will make her an invaluable resource for
our team during this important period of our
growth.”
“The Yield10 team brings a differentiated approach and new
insights to the identification of novel yield traits for commercial
food and feed crops, which has led to the discovery and evaluation
of a remarkable pipeline of yield traits,” said Dr. Brown. “The
outcomes they have reported to date have been impressive, and I
look forward to working with their team to contribute to the
Company's success.”
Dr. Brown joined The Yield Lab as Managing Director in 2017.
From 1989 to 2017, she served in a number of leadership positions
at Monsanto, most involving the development and global
commercialization of new traits for corn and oilseed crops
including soybean and canola. Dr. Brown most recently served as
Vice President, Science Strategy at Monsanto from 2014 to 2017 and
as a member of the Monsanto Leadership Council. Prior to that, she
was Vice President, Global Commercial Technology/Product
Development from 2008 to 2014 where she was responsible for
evaluating and launching the seed and trait pipeline, including
eight new biotech traits. In addition, she was Vice President,
Technology, Global Corn Business (1999-2004) and Vice President,
Technology, Oilseeds Business team (1998-1999). Dr. Brown earned a
Ph.D. at Indiana University, Bloomington, IN with a major in
Genetics/Molecular, Cellular and Developmental Biology. She earned
a B.S. at Hope College, Holland, MI with a double major in Biology
and Chemistry.
About Yield10
Bioscience
Yield10 Bioscience, Inc. is focused on developing new
technologies to achieve step-change improvements in crop yield to
enhance global food security. Yield10 has an extensive track record
of innovation based around optimizing the flow of carbon in living
systems.Yield10 is leveraging its technology platforms and unique
knowledge base to design precise alterations to gene activity and
the flow of carbon in plants to produce higher yields with lower
inputs of land, water or fertilizer. Yield10 is advancing several
yield traits it has developed in crops such as Camelina, canola,
soybean and rice. Yield10 is headquartered in Woburn, MA and has an
Oilseeds Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com.
(YTEN-G)
Safe Harbor for Forward-Looking
Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, those relating to the Company’s growth and the
potential for successful development and commercialization of new
yield traits, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including the risks and uncertainties
detailed in Yield10 Bioscience's filings with the Securities and
Exchange Commission. Yield10 assumes no obligation to update any
forward-looking information contained in this press release or with
respect to the matters described herein.
Contacts: Yield10
Bioscience:Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Media Inquiries: Eric FischgrundFischtank Marketing and
PReric@fischtankpr.com
Investor Relations:Bret ShapiroManaging Director, CORE
IR561-479-8566, brets@coreir.com
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Sep 2023 to Sep 2024